Axcella Health Inc (NASDAQ:AXLA) Stock Continues to Trend Lower: What’s The Buzz?

August 2, 2021

Clinical stage biotech firm Axcella Health Inc (NASDAQ:AXLA) saw its stock decline by 5.50% this past Friday and in light of the decline, it might be the right time for investors to perhaps figure out if it might be an opportunity to get into it at this point or not. The company, which is looking to go for new methods in order to treat complex conditions, announced its financial results…


Axcella (NASDAQ: AXLA) Activates Clinical Sites For EMMPOWER Study of AXA1665 in OHE

July 19, 2021

Axcella (NASDAQ: AXLA) has announced the activation of initial clinical study sites and patient screening for the global phase 2 clinical study of AXA1665. AXA1665 is Axcella’s multi-target oral drug candidate for reducing the risk of recurrent overt hepatic encephalopathy.  OHE is a severe condition with a devastating impact  Andres Duarte-Rojo, the principal study investigator, said, “OHE is a condition that has devastating consequences for patients and families and places…